This was confirmed by Jacene et al., who investigated 11 postmenopausal women with estrogen receptor-positive metastatic BC using 18F-FDHT PET/CT at baseline and at 6 and 12 weeks after starting SARM therapy with GTx-024 [71]. The gene discussed is ESR1; the disease is breast cancer.